ASURAGEN, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): The overall goal of this proposal is to expand the ca
ASURAGEN, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $225,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- ES13-009
- NAICS
- —
- Place of performance
- TX
- Period
- —
Description
DESCRIPTION (provided by applicant): The overall goal of this proposal is to expand the capability for molecular analyses of formalin fixed paraffin-embedded (FFPE) specimens through the use of whole transcriptome profiling with next generation sequencingtechnology (RNA-Seq). An end-to-end strategy will be developed that includes both experimental and analytical methods to address challenges specific to FFPE samples. This will enable the confident application of RNA-Seq to FFPE material to accurately profile: 1) transcriptional expression, 2) somatic mutations, and 3) chromosomal rearrangements. The strategy for the comprehensive workflow also includes resolving analysis challenges for FFPE RNA- Seq, including developing new bioinformatics tools to enhancethe identification of SNV and chromosomal rearrangements. The primary aims of this Phase I application are: Aim 1. Develop a rigorous qualification assay for FFPE RNA that is predictive of sequencing quality. Aim 2. Develop bioinformatics analysis